Dyumn Dwivedi

Dyumn Dwivedi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
UVUday Kumar B V
Uday Kumar B V
DDDyumn Dwivedi
Dyumn Dwivedi
Uddalak DasUddalak Das
Uddalak Das
The advent of CRISPR/Cas systems has revolutionized plant genome engineering, transitioning from traditional single-gene edits to sophisticated multiplex genome editing strategies capable of simultaneously targeting multiple loci. This review provides an in-depth examination of CRISPR-mediated multiplexing technologies in plants, emphasizing their molecular mechanisms, delivery systems, and transformative applications in crop improvement. We delineate the evolution of CRISPR systems from early programmable nucleases to diverse Class 2 effectors, including Cas9, Cas12, Cas13, and emerging ultra-compact variants like CasΦ and Cas14. We detail polycistronic gRNA expression platforms—such as tRNA-sgRNA arrays, ribozymes, and Csy4-mediated cleavage—that enable efficient multi-target editing within compact vectors. Furthermore, we explore advanced delivery modalities including Agrobacterium, biolistics, protoplast transfection, and viral vectors, optimized for recalcitrant plant systems. Applications span yield enhancement, disease resistance, abiotic stress tolerance, nutritional fortification, and de novo domestication. Critical challenges including off-target mutagenesis, mosaicism, chromosomal rearrangements, and regulatory constraints are addressed. Finally, we highlight AI-driven sgRNA design, multi-omics integration, and CRISPR libraries as pivotal tools to rationalize and scale multiplex editing. This synthesis underscores multiplex CRISPR as a cornerstone of next-generation plant breeding, with the potential to redefine global agriculture through precision trait stacking and rapid varietal development.

23 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Gopukumar S.TGopukumar S.T
Gopukumar S.T
DDDyumn Dwivedi
Dyumn Dwivedi
KGK. Gowri
K. Gowri
KVkarpaka valli
karpaka valli
CNChandralekha Nair
Chandralekha Nair
UDUddalak Das
Uddalak Das
Alzheimer's disease (AD), the predominant dementia etiology, imposes a $1.5 trillion global burden in 2025, exacerbated by inexorable failures in amyloid-tau-centric monotherapies amid <1% trial success rates. This review synthesizes cross-disciplinary pathobiology underpinning oncology drug repurposing for AD, leveraging inverse epidemiological antagonism and convergent hallmarks: aberrant neuronal cell-cycle re-entry (CDK5/p25, ERK-MAPK), proteostasis overload (HSP90-UPS-autophagy nexus), mTORC1 hyperactivation impairing lysosomal flux, kynurenine pathway (IDO1/TDO)-driven immunometabolic decoupling, PARP1-mediated NAD+ parthanatos, maladaptive neuroinflammation (PD-1/PD-L1 checkpoints, TAM-microglial skewing), and senescence-associated secretory phenotype (SASP)-amplified gliosis. Computational nomination pipelines—transcriptomic signature reversal (CMap/LINCS), network proximity in multi-omic knowledge graphs, and ligand-based docking—prioritize pleiotropic oncology agents: c-Abl/Src TKIs (nilotinib, bosutinib) enhancing autophagic Aβ/tau clearance; multikinase modulators (masitinib) resolving mast cell-microglial dyshomeostasis; rapalogs restoring proteostasis; IDO1 antagonists normalizing astrocytic lactate shuttling; PARPi mitigating genomic instability; HDACi reinstating synaptic epigenomes; and senolytics (dasatinib+quercetin) purging senescent glia. Phase I/II trials evince biomarker modulation (↓CSF p-tau, amyloid-PET; ↑autophagic flux) with geriatric-adapted dosing, yet underscore translational hurdles: BBB penetration, off-target liabilities, and polypharmacy in APOE ε4-enriched cohorts. A precision roadmap advocates orthogonal combinations (e.g., TKI+IDO1i), delivery-first PBPK modeling, and biomarker-anchored adaptive platforms to recalibrate AD's networked trajectory toward disease-modifying efficacy.